(Sharecast News) - Cambridge-based biotechnology firm Sareum Holdings announced on Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its patent application concerning crystalline forms of SDC-1801.
The AIM-traded company said SDC-1801 is its lead drug candidate, describing it as a dual TYK2/JAK1...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE